@gimedonc.bsky.social
PI3k mutations occur with ~ 35% prevalence. Are these outcomes worth performing genetic testing on all patients? Or maybe all resected CRC patients should get aspirin?
All I know is I now have a big bottle of aspirin in my clinic...
ascopubs.org/doi/10.1200/...
All I know is I now have a big bottle of aspirin in my clinic...
ascopubs.org/doi/10.1200/...
Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from a randomized placebo-controlled trial.
LBA125Background: Colorectal cancer (CRC) affects 1.9 million individuals globally each year. Among
patients with stage II-III CRC, 20-40% develop metastatic disease. Aspirin lowers
the incidence of a...
ascopubs.org
April 12, 2025 at 5:42 PM
PI3k mutations occur with ~ 35% prevalence. Are these outcomes worth performing genetic testing on all patients? Or maybe all resected CRC patients should get aspirin?
All I know is I now have a big bottle of aspirin in my clinic...
ascopubs.org/doi/10.1200/...
All I know is I now have a big bottle of aspirin in my clinic...
ascopubs.org/doi/10.1200/...
4. Aspirin and Celecoxib may have clinical benefit!?
5. ctDNA is here to stay, but we need to identify actionable strategies
5. ctDNA is here to stay, but we need to identify actionable strategies
January 26, 2025 at 11:55 AM
4. Aspirin and Celecoxib may have clinical benefit!?
5. ctDNA is here to stay, but we need to identify actionable strategies
5. ctDNA is here to stay, but we need to identify actionable strategies
α-CORRECT with a brutal sensitivity of only 48% in stage III CRC.
meetings.asco.org/abstracts-pr...
ctDNA in BTC!
meetings.asco.org/abstracts-pr...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
January 22, 2025 at 1:36 AM
α-CORRECT with a brutal sensitivity of only 48% in stage III CRC.
meetings.asco.org/abstracts-pr...
ctDNA in BTC!
meetings.asco.org/abstracts-pr...
More ctDNA data than you can shake a stick at!
Early conversion of ctDNA status a good predictor of patients appropriate for watch and wait in rectal cancer (not just 1, but 2 studies!).
meetings.asco.org/abstracts-pr...
meetings.asco.org/abstracts-pr...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
January 22, 2025 at 1:35 AM
More ctDNA data than you can shake a stick at!
Early conversion of ctDNA status a good predictor of patients appropriate for watch and wait in rectal cancer (not just 1, but 2 studies!).
meetings.asco.org/abstracts-pr...
meetings.asco.org/abstracts-pr...
Some real world data of immunotherapy use in MSI-H Colon Cancer showing benefit in patients with peritoneal mets (and more interestingly) significant benefit to primary tumor resection with a HR .44).
meetings.asco.org/abstracts-pr...
meetings.asco.org/abstracts-pr...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
January 22, 2025 at 1:35 AM
Some real world data of immunotherapy use in MSI-H Colon Cancer showing benefit in patients with peritoneal mets (and more interestingly) significant benefit to primary tumor resection with a HR .44).
meetings.asco.org/abstracts-pr...
meetings.asco.org/abstracts-pr...
OrigAMI-1 readout showing s 22% ORR to amivantamab monotherapy.
meetings.asco.org/abstracts-pr...
meetings.asco.org/abstracts-pr...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
January 22, 2025 at 1:35 AM
OrigAMI-1 readout showing s 22% ORR to amivantamab monotherapy.
meetings.asco.org/abstracts-pr...
meetings.asco.org/abstracts-pr...
Take away? Unclear if waiting for radiographic progression and surgery is best. Systemic therapy likely preferable in these patients... More studies to come soon.
December 28, 2024 at 3:45 PM
Take away? Unclear if waiting for radiographic progression and surgery is best. Systemic therapy likely preferable in these patients... More studies to come soon.
Wonder what the follow-up time is...
November 22, 2024 at 5:28 PM
Wonder what the follow-up time is...
Pan-cancer approvals like NTRK fusion inhibitors highlight the power of genomics: treating cancers by mutation, not just origin. With sequencing under $1000, we can identify actionable targets faster, bringing hope to patients with rare mutations and driving precision oncology forward.
November 19, 2024 at 3:06 PM
Pan-cancer approvals like NTRK fusion inhibitors highlight the power of genomics: treating cancers by mutation, not just origin. With sequencing under $1000, we can identify actionable targets faster, bringing hope to patients with rare mutations and driving precision oncology forward.